Vyne Therapeutics Inc (VYNE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 12-2020 | 12-2019 | 12-2018 | 12-2017 | 12-2016 | |
| Sales | 20,993 | 443 | 3,595 | 4,582 | 674 |
| Cost of Goods | 1,392 | 0 | 0 | N/A | N/A |
| Gross Profit | 19,601 | 443 | 3,595 | 4,582 | 674 |
| Operating Expenses | 272,539 | 96,316 | 78,487 | 34,175 | 15,006 |
| Operating Income | -252,546 | -95,873 | -74,892 | -29,593 | -14,332 |
| Interest Expense | 4,390 | 921 | 0 | 0 | 0 |
| Other Income | 1,110 | 1,440 | 941 | 517 | 264 |
| Pre-tax Income | -255,826 | -95,354 | -73,951 | -29,076 | -14,068 |
| Income Tax | -258 | -176 | 212 | N/A | N/A |
| Net Income Continuous | -255,568 | -95,178 | -74,163 | -29,076 | -14,068 |
| Net Income | $-255,568 | $-95,178 | $-74,163 | $-29,076 | $-14,068 |
| EPS Basic Total Ops | -141.73 | -201.80 | -206.30 | -409.35 | -202.88 |
| EPS Basic Continuous Ops | -141.79 | -201.75 | -206.29 | -409.51 | -202.94 |
| EPS Diluted Total Ops | -141.73 | -201.80 | -206.30 | -409.35 | -202.88 |
| EPS Diluted Continuous Ops | -141.79 | -201.75 | -206.29 | -409.51 | -202.94 |
| EPS Diluted Before Non-Recurring Items | -141.73 | N/A | N/A | N/A | N/A |
| EBITDA(a) | $-197,860 | $-95,523 | $-74,573 | $-29,519 | $-14,170 |